Example: bankruptcy

Targeted Tuberculin Testing Infection

Inside: Continuing Medical Education for Physicians and NursesTargeted Tuberculin Testingand treatment of Latent DEPARTMENT OF HEALTH & HUMAN SERVICESC enters for Disease Control and Prevention (CDC)Atlanta, GA 30333 June 9, 2000 / Vol. 49 / No. RR-6 RecommendationsandReportsInside: Continuing Medical Education for Physicians and NursesInside: Continuing Education Examination2 MMWRJune 9, 2000 Centers for Disease Control and Prevention .. Jeffrey P. Koplan, , material in this report was prepared for publication byNational Center for HIV, STD, and TB Prevention .. Helene D. Gayle, , of Tuberculosis Elimination .. Kenneth G. Castro, production of this report as an MMWR serial publication was coordinated inEpidemiology Program Office.

Inside: Continuing Medical Education for U.S. Physicians and Nurses and Treatment of Latent Tuberculosis Targeted Tuberculin Testing Infection U.S. DEPARTMENT OF HEALTH & …

Tags:

  Testing, Treatment

Information

Domain:

Source:

Link to this page:

Please notify us if you found a problem with this document:

Other abuse

Transcription of Targeted Tuberculin Testing Infection

1 Inside: Continuing Medical Education for Physicians and NursesTargeted Tuberculin Testingand treatment of Latent DEPARTMENT OF HEALTH & HUMAN SERVICESC enters for Disease Control and Prevention (CDC)Atlanta, GA 30333 June 9, 2000 / Vol. 49 / No. RR-6 RecommendationsandReportsInside: Continuing Medical Education for Physicians and NursesInside: Continuing Education Examination2 MMWRJune 9, 2000 Centers for Disease Control and Prevention .. Jeffrey P. Koplan, , material in this report was prepared for publication byNational Center for HIV, STD, and TB Prevention .. Helene D. Gayle, , of Tuberculosis Elimination .. Kenneth G. Castro, production of this report as an MMWR serial publication was coordinated inEpidemiology Program Office.

2 Barbara R. Holloway, DirectorOffice of Scientific and Health Communications .. John W. Ward, , MMWR SeriesRecommendations and Reports ..Suzanne M. Hewitt, J. WilsonProject F. BoydVisual Information D. R. ShaverTechnical Information SpecialistsThe MMWR series of publications is published by the Epidemiology Program Office,Centers for Disease Control and Prevention (CDC), Department of Health andHuman Services, Atlanta, GA CITATIONC enters for Disease Control and Prevention. Targeted Tuberculin Testing and treat-ment of latent tuberculosis Infection . MMWR 2000;49(No. RR-6):[inclusive pagenumbers].Vol. 49 / No. RR-6 MMWRiInside: Continuing Medical Education for Physicians and NursesContentsExecutive Summary.

3 1 Targeted Tuberculin Testing .. 1 treatment of Latent Tuberculosis Infection .. 2 Clinical and Laboratory Monitoring .. 4 Introduction .. 5 History of treatment of Latent Tuberculosis Infectionand Relevance to Tuberculosis Control .. 5 Relationship of Tuberculin Testing to treatment of LatentTuberculosis Infection .. 6 Change in Nomenclature .. 7 Scientific Rationale .. 7 Targeted Tuberculin Testing .. 7 Diagnosis of Latent Tuberculosis Infection .. 10 treatment of Latent Tuberculosis Infection .. 12 Recommendations .. 22 Implementation of Targeted Tuberculin Testing .. 22 Diagnosis of Latent Tuberculosis Infection .. 23 treatment of Latent Tuberculosis Infection .. 26 Priorities for Future Research .. 40 Diagnosis .. 40 Operational Research.

4 40 Efficacy Studies of New Drugs .. 41 Studies of Immunomodulators and Vaccines .. 41 Decision/Cost-Effectiveness Analyses .. 42 References .. 43iiMMWRJune 9, 2000 ATS/CDC Statement Committee on LatentTuberculosis InfectionMembership List, June 2000CO-CHAIRSD avid L. Cohn, Public HealthDenver, CORichard J. O Brien, for Disease Controland PreventionAtlanta, GAWRITING GROUPL awrence J. Geiter, Global TuberculosisFoundationRockville, MDFred M. Gordin, Medical CenterWashington, DCEarl Hershfield, of ManitobaWinnipeg, MB, CanadaC. Robert Horsburgh, Jr., University Schoolof MedicineAtlanta, GAJohn A. Jereb, for Disease Controland PreventionAtlanta, GATheresa J. Jordan, York University, New York, NYNew Jersey Medical SchoolNational Tuberculosis CenterNewark, NJJonathan E.

5 Kaplan, for Disease Controland PreventionAtlanta, GACharles M. Nolan, County Departmentof HealthSeattle, WAJeffrey R. Starke, , Children s HospitalHouston, TXZachary Taylor, for Disease Controland PreventionAtlanta, GAM. Elsa Villarino, , for Disease Controland PreventionAtlanta, GAVol. 49 / No. RR-6 MMWRiiiATS/CDC Statement Committee on LatentTuberculosis InfectionMembership List, June 2000 ContinuedMEMBERSN ancy J. Binkin, , for Disease Controland PreventionAtlanta, GANaomi N. Bock, University Schoolof MedicineAtlanta, GAKenneth G. Castro, for Disease Controland PreventionAtlanta, GARichard E. Chaisson, Hopkins UniversityBaltimore, MDGeorge W. Comstock, Hopkins UniversityHagerstown, MDMark S. Dworkin, for Disease Controland PreventionAtlanta, GAWafaa El-Sadr, , Hospital CenterNew York, NYPaula I.

6 Fujiwara, , of Tuberculosis ControlNew York, NYJeffrey C. Glassroth, of WisconsinMedical SchoolMadison, WIPeter Godfrey-Faussett, School of Hygieneand Tropical MedicineLondon, United KingdomMark J. Goldberger, , and Drug AdministrationRockville, MDJames L. Hadler, , of Public HealthHartford, CTPhilip C. Hopewell, Francisco General HospitalSan Francisco, CAMichael D. Iseman, Jewish Medicaland Research CenterDenver, CORichard F. Jacobs, of ArkansasLittle Rock, ARMack A. Land, of TennesseeCollege of Medicine MemphisMemphis, TNMark N. Lobato, for Disease Controland PreventionAtlanta, GARichard I. Menzies, Chest HospitalMontreal, PQ, CanadaivMMWRJune 9, 2000 ATS/CDC Statement Committee on LatentTuberculosis InfectionMembership List, June 2000 ContinuedGiovanni B.

7 Migliori, Salvadore MaugeriTradate, ItalyBess I. Miller, , for Disease Controland PreventionAtlanta, GAAlwyn Mwinga, Teaching HospitalLukasa, ZambiaEdward A. Nardell, HospitalCambridge, MAJames Neaton, of MinnesotaSchool of Public HealthMinneapolis, MNNoreen L. Qualls, for Disease Controland PreventionAtlanta, GALee B. Reichman, , Jersey Medical SchoolNewark, NJDavid N. Rose, Island Jewish HospitalNew Hyde Park, NYShelley R. Salpeter, Clara Valley Medical CenterSan Jose, CAHolger Sawert, , of Public HealthNonthaburi, ThailandPatricia M. Simone, for Disease Controland PreventionAtlanta, GADixie E. Snider, Jr., , for Disease Controland PreventionAtlanta, GAJoel Tsevat, , of CincinnatiMedical CenterCincinnati, OHAndrew A.

8 Vernon, for Disease Controland PreventionAtlanta, GAChristopher C. Whalen, Western Reserve UniversityCleveland, OHTimothy C. Wilcosky, Triangle InstituteResearch Triangle Park, NCVol. 49 / No. RR-6 MMWRvNOTICEThis report is being published with the permission of the American ThoracicSociety and as a courtesy to the MMWR readership. It is an adaptation of areport published in the American Journal of Respiratory and Critical CareMedicine 2000;161:S221 9, 2000 Vol. 49 / No. RR-6 MMWR1 Targeted Tuberculin Testing and treatment of LatentTuberculosis InfectionThis Official Statement of the American Thoracic Society was adopted by theATS Board of Directors, July 1999. This is a Joint Statement of the AmericanThoracic Society (ATS) and the Centers for Disease Control and Prevention(CDC).

9 This Statement was endorsed by the Council of the Infectious DiseasesSociety of America (IDSA), September 1999, and the sections of this Statementas it relates to infants and children were endorsed by the American Academy ofPediatrics (AAP), August SUMMARY This statement provides new recommendations for Targeted Tuberculin Testing andtreatment regimens for persons with latent tuberculosis Infection (LTBI) and updatespreviously published guidelines (1,2). This statement is issued in recognition of theimportance of these activities as an essential component of the TB Elimination Strat-egy promoted by the Public Health Service Advisory Council on the Elimination ofTuberculosis, and reports the deliberations of expert consultants convened by theAmerican Thoracic Society (ATS) and Centers for Disease Control and Prevention (CDC).

10 Isoniazid for 6 12 mo has been the mainstay of treatment for LTBI in the UnitedStates for more than 30 yr. However, the application of isoniazid for LTBI has beenlimited because of poor adherence, due to the relatively long duration of treatmentrequired, and because of concerns about toxicity. Therefore, there has been interest inthe development of shorter, rifampin-based regimens as alternatives to isoniazid forthe treatment of LTBI. During the past decade, a series of studies of short-course treatment of LTBI in persons with human immunodeficiency virus (HIV) Infection hasbeen undertaken. The results of these trials have recently become available, and the in-depth analyses of these and prior studies of isoniazid form the scientific basis of thetreatment guidelines presented in this report.


Related search queries